Published in Medical Verdicts and Law Weekly, July 26th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Alba Therapeutics.
Report 1: Alba Therapeutics Corporation today announced preliminary results from its Phase IIa clinical trial for AT-1001 in subjects with Celiac Disease (CD), an autoimmune disease affecting over 3 million people in the United States. Alba's study, the first Phase IIa trial in CD and the first to assess dosing requirements for AT- 1001 in CD, was designed to evaluate the safety, tolerability and efficacy of multiple doses of AT- 1001 in CD subjects during a 2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.